Natixis Advisors LLC Boosts Stock Position in Cencora, Inc. (NYSE:COR)

Natixis Advisors LLC increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 3.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 139,028 shares of the company's stock after acquiring an additional 5,198 shares during the period. Natixis Advisors LLC owned approximately 0.07% of Cencora worth $31,292,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New Millennium Group LLC acquired a new stake in shares of Cencora in the second quarter worth $26,000. TFO Wealth Partners LLC acquired a new position in shares of Cencora in the 1st quarter valued at about $30,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter worth about $30,000. Concord Wealth Partners purchased a new position in Cencora during the third quarter valued at approximately $30,000. Finally, LRI Investments LLC acquired a new position in Cencora in the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares of the company's stock, valued at $67,223,750.40. The trade was a 7.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 15.80% of the company's stock.

Cencora Price Performance

NYSE COR traded up $2.63 during trading hours on Monday, hitting $242.87. 1,243,183 shares of the company's stock traded hands, compared to its average volume of 1,409,300. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The firm's 50-day moving average is $232.62 and its 200-day moving average is $231.04. Cencora, Inc. has a 52-week low of $194.56 and a 52-week high of $251.56. The company has a market capitalization of $47.86 billion, a PE ratio of 32.29, a PEG ratio of 1.60 and a beta of 0.44.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be paid a dividend of $0.55 per share. This is a positive change from Cencora's previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.91%. Cencora's dividend payout ratio is presently 27.16%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of analyst reports. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. UBS Group increased their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Finally, Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and an average price target of $271.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.